Renergen Limited and ASP Isotopes Inc. have recently provided an update on the progress of their Scheme of Arrangement. Key milestone transaction approvals have been received, including the approval from the Competition Commission. The written consent to the transfer of Renergen Shares in terms of the Offer has been obtained from the Industrial Development Corporation of South Africa and the United States International Development Finance Corporation.
The deadline for the fulfillment of the remaining Conditions has been extended to January 30, 2026. Additionally, the date for Renergen’s repayment of the funding advanced to it has also been extended to the same date.
It is noted that the fulfillment of conditions for a transaction of this nature can require additional time when regulatory or third-party approvals are needed.
Both companies remain committed to fulfilling the remaining Conditions and obtaining the required approvals as quickly as possible.
The details of the updated salient dates and times for the Scheme are to be announced once the remaining Conditions have been fulfilled or waived.
The Independent Board of Renergen and the board of directors of ASP Isotopes have accepted responsibility for the information contained in the announcement.
The announcement was made on November 27, 2025. The market has reacted to these announcements by moving the company's shares 5.07% to a price of $6.22. If you want to know more, read the company's complete 8-K report here.
